accurate etiologic diagnosis is essential for infection of the central nervous system (CNS infections). The diagnostic value of metagenomic sequencing generation (mNGS), a powerful platform that appears, remains to be studied in the CNS infections.
We conduct a prospective cohort study comparing single-center for mNGS with conventional methods including culture, smear and others 248 suspected CNS infectious patients were enrolled and clinical data were recorded.
RESULTS mNGS reported a sensitivity of 90.00% (9/10) in patients with culture-positive without empirical treatment and 66.67% (6/9) in patients treated empirically. Detected addition of 48 bacteria and fungi in culture-negative patients, mNGS provide higher detection rate compared with culture in patients with (34.45% vs. 7.56%, McNemar test, p <0.0083) or without empirical therapy ( 50.00% vs 25.00%, McNemar test, p> 0.0083).
Compared with the conventional method, the positive percent agreement and negative percent agreement was 75.00% and 69.11% separately. mNGS detection rate was significantly higher in patients with cerebrospinal fluid (CSF) WBC> 300 * 106 / L, CSF protein> 500 mg / L or glucose ratio ≤ 0.3. mNGS sequencing reads correlated with CSF WBC, the ratio of glucose and the development of clinical disease.
mNGS showed satisfactory diagnostic performance in CNS infections and has a superior detection rate overall culture. mNGS probably held diagnostic benefit, especially in patients treated empirically. CSF laboratory results are statistically relevant mNGS detection rate, and mNGS can dynamically monitor the progression of the disease.
accurate etiologic diagnosis is essential for infection of the central nervous system (CNS infections). The diagnostic value of metagenomic sequencing generation (mNGS), a powerful platform that appears, remains to be studied in the CNS infections.We conduct a prospective cohort study comparing single-center for mNGS with conventional methods including culture, smear and others 248 suspected CNS infectious patients were enrolled and clinical data were recorded.
RESULTS
mNGS reported a sensitivity of 90.00% (9/10) in patients with culture-positive without empirical treatment and 66.67% (6/9) in patients treated empirically. Detected addition of 48 bacteria and fungi in culture-negative patients, mNGS provide higher detection rate compared with culture in patients with (34.45% vs. 7.56%, McNemar test, p <0.0083) or without empirical therapy ( 50.00% vs 25.00%, McNemar test, p> 0.0083). Compared with the conventional method, the positive percent agreement and negative percent agreement was 75.00% and 69.11% separately. mNGS detection rate was significantly higher in patients with cerebrospinal fluid (CSF) WBC> 300 * 106 / L, CSF protein> 500 mg / L or glucose ratio ≤ 0.3. mNGS sequencing reads correlated with CSF WBC, the ratio of glucose and the development of clinical disease.
mNGS showed satisfactory diagnostic performance in CNS infections and has a superior detection rate overall culture. mNGS probably held diagnostic benefit, especially in patients treated empirically. CSF laboratory results are statistically relevant mNGS detection rate, and mNGS can dynamically monitor the progression of the disease.
Description: A polyclonal antibody against TRMT112. Recognizes TRMT112 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200
Description: The protein encoded by this gene is a transcriptional regulator and oncoprotein that may be involved in hematopoiesis, apoptosis, development, and cell differentiation and proliferation. The encoded protein can interact with CTBP1, SMAD3, CREBBP, KAT2B, MAPK8, and MAPK9. This gene can undergo translocation with the AML1 gene, resulting in overexpression of this gene and the onset of leukemia. Several transcript variants encoding a few different isoforms have been found for this gene.
Description: The protein encoded by this gene is a transcriptional regulator and oncoprotein that may be involved in hematopoiesis, apoptosis, development, and cell differentiation and proliferation. The encoded protein can interact with CTBP1, SMAD3, CREBBP, KAT2B, MAPK8, and MAPK9. This gene can undergo translocation with the AML1 gene, resulting in overexpression of this gene and the onset of leukemia. Several transcript variants encoding a few different isoforms have been found for this gene.
Description: The protein encoded by this gene is a transcriptional regulator and oncoprotein that may be involved in hematopoiesis, apoptosis, development, and cell differentiation and proliferation. The encoded protein can interact with CTBP1, SMAD3, CREBBP, KAT2B, MAPK8, and MAPK9. This gene can undergo translocation with the AML1 gene, resulting in overexpression of this gene and the onset of leukemia. Several transcript variants encoding a few different isoforms have been found for this gene.
Description: The protein encoded by this gene is a transcriptional regulator and oncoprotein that may be involved in hematopoiesis, apoptosis, development, and cell differentiation and proliferation. The encoded protein can interact with CTBP1, SMAD3, CREBBP, KAT2B, MAPK8, and MAPK9. This gene can undergo translocation with the AML1 gene, resulting in overexpression of this gene and the onset of leukemia. Several transcript variants encoding a few different isoforms have been found for this gene.
TRMT112 (untagged)-Human tRNA methyltransferase 11-2 homolog (S. cerevisiae) (TRMT112)
Description: A polyclonal antibody against TRMT112. Recognizes TRMT112 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against TRMT112. Recognizes TRMT112 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against TRMT112. Recognizes TRMT112 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: Human TRMT112 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.
